38. Meet-the-Professor: Hospital Avoidance Utilizing Outpatient Antibiotic Therapy
Session: Meet-the-Professor Session: Outpatient Antibiotic Therapy to Address Preventable Hospitalizations
Thursday, October 3, 2013: 7:35 AM
Room: The Moscone Center: 250-262
Russell Petrak, MD, FIDSA, Metro Infectious Diseases Consultants, LLC, Burr Ridge, IL

Russell M. Petrak is a board certified infectious disease specialist practicing in the Chicago area. He is one of the founding members and managing partner of Metro Infectious Disease Consultants, L.L.C. (MIDC), a 70 member fully integrated ID group servicing 100 hospitals and 22 offices. Founded in 1994, MIDC provides comprehensive infectious disease services including inpatient and outpatient consultation, traveler’s immunizations, and outpatient antibiotic therapy throughout Northern Illinois, Indiana, Iowa, Michigan and Arizona. Dr. Petrak was trained at Rush Medical College and completed his internship, residency, and fellowship in infectious disease at Rush-Presbyterian-St. Luke’s Medical Center in Chicago. His first six years of practice were spent as teaching faculty at a Westside Chicago hospital before being appointed Academic Director of Medicine. As such, he served as program director for several residency programs, and directly supervised the subspecialty departments of internal medicine. In 1994 he left this role to start MIDC.
In 1997, he became a member of the Clinical Affairs Committee of IDSA, and served as Chairman from 2000-2003. He remains an active member of the IDSA Outpatient Parenteral Antimicrobial Therapy Task Force, and was recently the lead author of an article entitled “The Value of an Infectious Disease Specialist”.
For the past 12 years, Dr. Petrak has been invited to speak at the annual IDSA Fellows Meeting, where he has lectured on topics such as, “How to Interview for an ID Job”, and “The Art of Infectious Disease Consultation”.

<< Previous Presentation | Next Presentation

Findings in the abstracts are embargoed until 12:01 a.m. PST, Oct. 2nd with the exception of research findings presented at the IDWeek press conferences.